Welcome to our dedicated page for Oaktree Specialty SEC filings (Ticker: OCSL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Credit investors know the challenge: Oaktree Specialty Lending鈥檚 fair-value marks, leverage tests, and non-accrual loan tables sprawl across hundreds of pages. If you have ever typed 鈥淥aktree Specialty Lending insider trading Form 4 transactions鈥� or 鈥淥aktree Specialty Lending quarterly earnings report 10-Q filing,鈥� you have already felt that pain. Stock Titan eases it with AI-powered summaries that turn footnotes into clear talking points and flag portfolio moves the moment they hit EDGAR.
Need real-time alerts for 鈥淥aktree Specialty Lending Form 4 insider transactions real-time鈥�? Our platform streams every Form 4, highlights executive stock purchases, and links them to credit events disclosed in an 8-K. Want 鈥淥aktree Specialty Lending SEC filings explained simply鈥�? One click reveals AI glossaries beside each 10-K, while side-by-side charts compare net investment income across quarters. You will also find: 鈥淥aktree Specialty Lending earnings report filing analysis,鈥� 鈥渦nderstanding Oaktree Specialty Lending SEC documents with AI,鈥� and, for deep dives, 鈥淥aktree Specialty Lending annual report 10-K simplified.鈥�
Because BDCs live or die by capital structure moves, we surface every 鈥淥aktree Specialty Lending proxy statement executive compensation鈥� line item, track dividend coverage, and decode 鈥淥aktree Specialty Lending 8-K material events explained.鈥� From first-lien loan concentration to sector exposure shifts, our expert analysis and real-time updates keep you ahead. Monitor insider trades, compare quarter-over-quarter NAV, and download AI summaries of every filing type鈥�10-K, 10-Q, 8-K, Form 4, DEF 14A鈥攚ithout parsing dense legalese yourself.
Smith & Nephew (NYSE:SNN) posted another solid period in its 6-K.
- Q2 2025 revenue rose to $1.553 bn, +7.8% reported (+6.7% underlying); H1 revenue reached $2.961 bn, +4.7% reported (+5.0% underlying) despite two fewer trading days.
- H1 trading profit climbed 11.2% to $523 m; trading margin widened 100 bps to 17.7%, while operating profit jumped 30.6% to $429 m.
- Free cash flow surged to $244 m (H1 2024: $39 m) on 93% cash-conversion; net debt/adj. EBITDA stands at 1.8脳.
- Interim dividend increased 4.2% to 15.0垄 per share and a $500 m share-buyback was announced for H2 2025.
- FY 2025 outlook unchanged: ~5% underlying revenue growth (5.5% reported) and 19-20% trading margin, absorbing a $15-20 m tariff hit.
Growth was broad-based: Orthopaedics +5.0% underlying, Sports Medicine & ENT +5.7%, Advanced Wound Management +10.2%. Recent product launches generated 75% of H1 growth, and the 12-Point Plan cut inventory by $69 m (-46 DSI days). Orthopaedics margin improved 230 bps; Advanced Wound margin +160 bps.
Key risks: China VBP pressure, Emerging-Markets H1 underlying 鈭�0.9%, potential 2026 Medicare changes to skin substitutes, higher trading-tax rate (19.8% vs. 17.8%) and $15-20 m tariff headwind. Nonetheless, operational gains and balance-sheet strength underpin continued cash returns.
FAQ
What is the current stock price of Oaktree Specialty (OCSL)?
What is the market cap of Oaktree Specialty (OCSL)?
What is the core business of Oaktree Specialty Lending Corporation?
How does OCSL generate its revenue?
Which types of debt financing does Oaktree Specialty Lending offer?
What market sectors does OCSL invest in?
How does the company position itself in the financial markets?
What is the regulatory status of Oaktree Specialty Lending Corporation?
How does OCSL differentiate itself from competitors?
What are the key components of OCSL's investment strategy?
